Viventia finds public path via Eleven

Ophthalmic therapeutics company Eleven Biotherapeutics Inc. (NASDAQ:EBIO) acquired cancer company Viventia Bio Inc. (Mississauga, Ontario), which had been in the IPO queue.

The combined company will retain Eleven's name and will primarily develop Viventia's pipeline. It will seek to develop oncology therapeutics based on antibody fragments genetically fused to cytotoxic proteins. Viventia CEO Stephen Hurly will be its president and CEO. ...